



**VIJAYA
DIAGNOSTIC
CENTRE**

February 13, 2023

To,
Listing Department
National Stock Exchange Of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
NSE Symbol. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25th floor, Dalal Street,
Mumbai - 400 001
BSE Scrip Code. 543350

Dear Sir/Madam,

Sub: Investor Presentation.

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation that would be used in the Investors / Analysts earnings conference call scheduled to be held on February 14, 2023 at 11:30 a.m. IST.

Please take the information on record.

Thanking you,

For Vijaya Diagnostic Centre Limited

SUPRITA

SURA REDDY

S Suprita Reddy
Chief Executive Officer

Digitally signed by SUPRITA SURA REDDY
DN: cn=PERSONAL, o=8913,
pseudoym=5662ba9799943a183579a4997c5a036,
2.5.4.20=aa27880c0e6daa165c1a70502ca49baa12d84e,
34973ad0ca3af2080f4ec376, postalCode=500033,
st=Telangana,
serialNumber=315074dfb19016701923f8b5a0f21556
b5659ba77f420f4c8b9a31d383589e, cn=SUPRITA
SURA REDDY
Date: 2023.02.13 15:01:43 +05'30'

Encl.: As Above



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited

Q3 & 9MFY23 Earnings Presentation

February 13, 2023

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Vijaya Diagnostic Centre Limited (the ‘Company’)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



**VIJAYA
DIAGNOSTIC
CENTRE**

Q3 & 9MFY23 Financial Performance

Operational & Financial Highlights – Q3 FY23




2.49 Mn
Tests

0.77 Mn
Footfalls



INR 1,131.2 Mn
Revenue



117
Centres
(opened 5
closed 1)



INR 442.9 Mn
EBIDTA

39.1%
EBIDTA Margin



95%
B2C Revenue



INR 163.6 Mn
Profit After Tax

14.5%
PAT Margin

INR 183.5 Mn
Normalised Profit After Tax

16.2%
Normalised PAT¹ Margin



Commenting on the Q3FY23 results performance, Ms. Suprita Reddy, CEO at Vijaya Diagnostic Centre Ltd. said:

“We are pleased to report steady performance during a seasonally soft quarter for the industry. The volume trends that were slow in the months of October and November, saw a significant improvement in December and we hope to carry this momentum into the upcoming quarter.


Our ongoing efforts to expand the network through the addition of new hubs and spokes has been progressing well. During this quarter, we opened 5 centers including one of its kind facility at Punjagutta. Our newly opened state-of-the-art facilities in Punjagutta and Rajahmundry have received an overwhelmingly positive response from our customers. Additionally, our efforts to improve digital operations are proceeding smoothly, and we anticipate that these initiatives will considerably improve operational efficiency and enhance customer experience across all of our centers.

Looking ahead, the outlook for the diagnostics industry remains positive, with increasing demand for advanced medical services and a growing emphasis on preventive healthcare. We remain confident that our integrated diagnostics offerings, well-established brand and our robust B2C network will enable us to capitalize on the huge market opportunity.”

Key Financial Highlights – Q3 & 9M FY23

(INR Mn)

Revenue from Operations




Shift YoY (%)

2.1%

-2.3%


EBITDA & EBITDA Margin (%)



-7.4%

-14.7%

PAT & PAT Margin (%)




Shift YoY (%)

-35.3%

-33.5%

Normalised PAT & PAT Margin (%)




-31.6%

-31.0%


Revenue Mix – Q3 & 9MFY23

(In %)

Radiology vs. Pathology Breakdown





Non-COVID & COVID Allied Breakdown



Non-COVID YoY (%)	9.8%
COVID YoY (%)	-89.2%


B2C Contribution – Q3 FY23 & 9MFY23



Non-COVID YoY (%)	12.2%
COVID YoY (%)	-85.2%

Recorded its highest ever December monthly volumes in a seasonally soft quarter

- The Company experienced lower volumes during the month of October and November due to the festive season. However, the Company registered a strong uptick in its operational performance during the month of December



VDCL to launch state of the art facility in Tirupathi, Andhra Pradesh

- The 10,000 + sq.ft. facility at **Tirupathi, Andhra Pradesh is expected to be inaugurated in February 2023**
 - The center will be equipped with advanced radiology modalities and equipment, including a 3T MRI, CT scan, Gamma Camera, basic radiology and an automated lab

Financial Performance Q3FY23

- Revenue from Operations increased by 2.1% YoY to Rs. 1,131 Mn, Non-Covid Revenues grew by 9.8% YoY
 - During Q3FY23, the Non-COVID business comprised 99% of total revenue share as against 92% revenue share in Q3FY22
 - Wellness share in Q3FY23 was up at 12.9% as against 8.5% in Q3FY22
 - Revenue composition from B2C segment stood at 95%
- EBITDA stood at Rs. 443 Mn. EBITDA margin for the quarter was 39.1% as against 43.2% in Q3FY22
 - Healthy non covid revenue coupled with operating leverage assisted margin performance despite costs on account of new centres
- PAT stood at Rs. 164 Mn. translating into a PAT margin of 14.5%
- Normalised PAT stood at Rs. 184 Mn. translating into a PAT margin of 16.2%



Financial Performance 9MFY23

- Revenue from Operations decreased by 2.3% YoY to Rs. 3,382 Mn, Non-Covid Revenues grew by 12.2% YoY
 - Wellness share in 9MFY23 was up at 11.7% as against 6.3% in 9MFY22
 - Revenue composition from B2C segment continued to stay strong at 95%
- EBITDA stood at Rs. 1,329 Mn. EBITDA margin for 9MFY23 was 39.3%
- PAT stood at Rs. 571 Mn. translating into a PAT margin of 16.9% in 9MFY23
- Normalised PAT stood at Rs. 625 Mn. translating into a PAT margin of 18.5% in 9MFY23

Indian Diagnostics Market expected to Grow at a Healthy Trajectory


Indian Diagnostics Market

(INR Bn)




Segment-wise breakup of Indian Diagnostic Market

Radiology Pathology




Key Financial Highlights


Cash flow from Operations / EBITDA (%)



Cash & Cash Equivalents (INR Mn)



Working Capital Days¹




- Cash flow from Operations stood at Rs. 1,190 mn. for 9M ended Dec. 31, 2022
- Cash and Cash Equivalents stood at Rs. 2,425 mn. as on Dec. 31, 2022
- Working Capital Days continues to remain negative at -10 in Q3FY23


Note 1: Quarterly Revenue figures are annualized

Key Operational Highlights


Tests Performed (# in Million)




Footfalls (# in Million)




Tests / Footfalls (# in Million)



Revenue per Test (INR)



Revenue per Footfall (INR)



- Company recorded steady growth in No. of tests on YoY basis led by Non-COVID customers in 9MFY23

Consolidated Profit & Loss Account – Q3 & 9M FY23



(INR Mn)

Particulars	Q3 FY23	Q3 FY22	Y-o-Y	Q2 FY23	Q-o-Q	9M FY23	9M FY22	Y-o-Y
Revenue from operations	1,131.2	1,107.8	2.1%	1,207.5	-6.3%	3,382.3	3,461.7	-2.3%
Cost of materials consumed	136.7	163.0	-16.2%	166.5	-17.9%	433.5	536.2	-19.2%
Employee benefits expense	197.3	182.2	8.3%	197.4	0.0%	589.5	514.6	14.6%
Other expenses	354.3	284.3	24.7%	356.1	-0.5%	1,030.1	852.5	20.8%
EBITDA	442.9	478.3	-7.4%	487.4	-9.1%	1,329.2	1,558.3	-14.7%
EBITDA Margin (%)	39.1%	43.2%	-410 bps	40.4%	-130 bps	39.3%	45.0%	-570 bps
Other income	35.6	32.0	11.1%	33.0	7.7%	96.3	96.4	-0.1%
Depreciation and amortization expense	202.8	130.1	56.0%	159.0	27.6%	503.6	374.1	34.6%
EBIT	275.6	380.2	-27.5%	361.4	-23.8%	921.9	1,280.7	-28.0%
Finance costs	55.4	41.8	32.7%	48.7	13.7%	151.8	121.2	25.3%
Profit before Tax	220.2	338.5	-34.9%	312.7	-29.6%	770.1	1,159.5	-33.6%
Tax expenses	55.6	83.9	-33.7%	78.0	-28.7%	195.3	291.7	-33.0%
Profit before Minority Interest	164.6	254.6	-35.4%	234.7	-29.9%	574.8	867.8	-33.8%
Minority Interest	0.9	1.7	-48.4%	1.4	-36.6%	3.4	8.2	-58.1%
Profit after Tax (PAT)	163.6	252.9	-35.3%	233.3	-29.9%	571.4	859.7	-33.5%
PAT Margin (%)	14.5%	22.8%	-830 bps	19.3%	-480 bps	16.9%	24.8%	-790 bps
EPS – Basic (INR) *	1.6	2.5	-35.9%	2.3	-28.1%	5.6	8.4	-33.3%
Normalised PBT	246.8	359.1	-31.3%	335.8	-26.5%	841.8	1,220.7	-31.0%
Normalised PBT Margin (%)	21.8%	32.4%	-1,060 bps	27.8%	-600 bps	24.9%	35.3%	-1,040 bps
Normalised PAT	183.5	268.4	-31.6%	250.6	-26.8%	624.9	905.4	-31.0%
Normalised PAT Margin (%)	16.2%	24.2%	-800 bps	20.8%	-460 bps	18.5%	26.2%	-770 bps

*Not annualized

Normalised PBT/PAT is excluding the National interest & Depreciation as per IND AS 116, Leases.



**VIJAYA
DIAGNOSTIC
CENTRE**

Company Overview

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 117 state-of-the-art centres spread across 19 cities



Mission

Our Mission is to make the patient's medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician



Vision

Our Vision is to provide reliable and accurate diagnostic services to our customers, at affordable prices, in a customer-centric manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional



40+

Years of Experience

Experience in delivering Quality Diagnostic Service at affordable prices



117

Centres

State-of-the-art Facilities with Best-in-class Technology



Quality



19

Cities across India

Largest integrated player in South India



200+

Doctors

Radiologists, Pathologists & Microbiologists



Reliable & Accurate Diagnostics



~3.6 Mn

Footfalls

Trusted by every Age group



~9.3 Mn


Tests

Most preferred Diagnostic Centre




at Affordable Prices

Footfalls & Tests for 12 months ending Mar 2022




*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

At the Forefront of Introducing New Technologies



Our Pillars of Strength




One of the leading players in India's high growth diagnostics market

Telangana and Andhra Pradesh Market Size

Telangana and Andhra Pradesh (44 - 46% of South India)

(INR Bn)




Growth Drivers:


- Rising NCDs in the states
- Increasing share of aged population
- Rising health awareness
- Increasing health insurance penetration
- Conducive government healthcare schemes

Vijaya's Core Geographies

Dominant Position in Telangana & Andhra Pradesh



Integrated Diagnostic service provider with extensive network...



Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT)

Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT)

Spokes = Lab Samples Collection + Basic Radiology

Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.

Complete Range of Diagnostic Services under One Roof

Comprehensive and high quality integrated diagnostic services through our operational network



High brand recall driving customer stickiness

Customer Centric Approach



Quality Diagnostic Services



Higher brand recall

High share of walk-in customers

Sticky individual customer


“One of the Best Healthcare Brands 2021”

by The Economic Times in 2021

“For excellence in Quality and Accuracy”


under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021

B2C Revenue




Operational Metrics

(INR)



Robust Technical Capabilities with State-of-the-art IT Infrastructure



Key Suppliers



- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Advanced Software to Manage Clinical Data



Advance Laboratory Information Management System (LIMS)



Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling...



Standardization across our operations



Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**



Reduce incidence of errors due to **Low Human Intervention**



Provide **Uniform Experience** to customers from booking appointments to accessing reports online



Monitor **Technical Operations**



Dr. S Surendranath Reddy - Executive Chairman

- Founder of Vijaya with 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Provisional degree of Doctor of Medicine in Radiology



S Geeta Reddy - Non-Executive Director

- Enrolled as advocate with Andhra Pradesh High Court in 1986
- Holds a Bachelor's degree in Law from Osmania University



Sunil Chandra Kondapally - Executive Director

- Been with Vijaya since 2002 and 17+ years of experience in healthcare
- Holds Bachelor's degree in Electrical Engineering from Florida State University



Dr. D Nageshwar Reddy - Non-executive, Independent Director

- Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad
- Awarded Padma Shri and Padma Bhushan by Government of India
- D.M in Gastroenterology from PGIMER Chandigarh



Shekhar Prasad Singh - Non-executive, Independent Director

- Ex-Chief Secretary to Government of Telangana
- Retired IAS officer of 1983 batch



Satyanaryana Murthy Chavali - Non-executive, Independent Director

- Ex-CEO of Aurigene Discovery Technologies Ltd.
- Holds BTech from IIT, Madras and MBA from IIM, Bangalore



Dr. Manjula Anagani - Non-executive, Independent Director

- Clinical Director and Head of Department of centre of women and childcare at Care hospitals
- Awarded Padma Shri by Government of India
- MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences



Dr. S. Surendranath Reddy

Executive Chairman

- 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Provisional degree of Doctor of Medicine in Radiology
- He is a life member of the Indian Radiological and Imaging Association.



Mr. Sunil Chandra Kondapally

Executive Director

- With Vijaya since incorporation and experienced in operations, quality accreditation, finance, marketing and network expansion departments
- 17+ Years of experience in healthcare industry & founded Trikona Pharmaceuticals Pvt. Ltd. (2016) and QPS Bioserve India Pvt. Ltd. (2004)
- Holds bachelor's degree in electrical engineering from Florida State University



Ms. Suprita Reddy

Chief Executive Officer

- With Vijaya since 2003 and heads overall strategy, clinical excellence, operations and expansion of the company
- Awarded Women Leadership Award in Healthcare by ABP in 2019
- Holds bachelors degree in commerce from Osmania University



Mr. Narasimha Raju K.A


Chief Financial Officer

- Associated with Vijaya from June 2017 to Nov 2020 and rejoined in March 2021
- 14+ years of experience in audit, financial reporting, regulatory compliance and accounting advisory
- Previously worked with SR Baltliboi & Co., NSL Renewable Power Pvt. Ltd. etc
- Holds bachelor's degree of commerce from Osmania University and member of the Institute of Chartered Accountants of India

Awards & Accolades

<p>Best Healthcare Brands 2022</p>  <p>2022 Presented by The Economic Times</p>	<p>Healthcare Leadership Awards 2022</p>  <p>2022 Presented by eHealth Magazine</p>	<p>Pride of India Brands Award 2022</p>  <p>2022 Presented by The Best of South Awards</p>	<p>One of the Best Healthcare Brands 2021</p>  <p>2021 Presented by The Economic Times</p>	<p>Indo Global Award for Healthcare Excellence</p>  <p>2021 Presented by Indian Economic Development & Research Association</p>	<p>Company of the Year - Healthcare</p>  <p>2021 Presented by TV9 Network and SAP</p>
<p>Leading Diagnostic Chain of the Year</p>  <p>2021 Presented by Diagnostic Leadership Summit</p>	<p>India's Greatest Brands 2020-21 Pride of Nation</p>  <p>2021 Presented by United Research Services</p>	<p>India's Greatest Brands 2020-21 Pride of Nation</p>  <p>2021 Presented by United Research Services</p>	<p>Leading Diagnostics with Excellence in Quality & Safety</p>  <p>2021 Presented by Diagnostic Leadership Summit</p>	<p>Most Trusted and Best Quality Diagnostic services in India</p>  <p>2020 Presented by Times Healthcare Achievers</p>	<p>Healthcare Entrepreneur of the Year – Dr. Surendra Reddy</p>  <p>2019 Presented by Six Sigma Healthcare</p>
<p>Fastest Growing Brands (Pride of the Nation)</p>  <p>2019 Presented by United Research Services</p>	<p>Best Diagnostic Centre of the Year</p>  <p>2019 Presented by Times Healthcare Achievers</p>	<p>Leading Chain of Diagnostics & Imaging</p>  <p>2019 Presented by Indian Medical Association, Telangana state and Messe India</p>	<p>Best Diagnostic Service Provider of the Year</p>  <p>2019 Presented by Six Sigma Healthcare</p>	<p>Most Trusted Diagnostic Centre of the Year</p>  <p>2019 Presented by Indo-Arab Leaders Summit & Awards</p>	<p>Telangana Healthcare Leadership Awards</p>  <p>2018 Presented by Telangana Government</p>

Shareholding Pattern as of 31st Dec 2022



Marquee Institutional Investors

- Wasatch Advisors
- Nippon Life India
- Aberdeen Standard Investments
- Axis Mutual Fund
- Fidelity Group
- DSP Healthcare Fund
- Abu Dhabi Investment Authority
- Goldman Sachs

As on 31st December 2022

DIIs: Mutual Funds, AIF's and QIB's


Others: Retail, Bodies Corporate and others



**VIJAYA
DIAGNOSTIC
CENTRE**

Strategy Going Forward

Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh



Leveraging Existing Presence

Given under-penetration of diagnostic market, we will continue to focus on



Opening additional diagnostic centres through owned model



Expanding network through setting up spokes and hubs in existing catchment areas



Adding reference laboratories in our existing core geographies



Consolidate Leading Position

Given our significant presence and operational experience in Telangana and Andhra Pradesh, we intend to deepen our penetration and increase customer base by



Enhancing laboratory capacity and test menu by adding latest technologies




Offering value added services



Physician engagements (by conducting continuous medical education programs)

Expand in Adjacent Geographies & East India




South India Strategy

- Expand in concentric circles given our hub and spoke model
- Establish presence in adjacent geographies
- Identified key cities and towns which are underserved and our brand is well-regarded
- Wider geographic reach will expand our customer base leading to better profitability by leveraging our infrastructure

East India Strategy

- Expand presence in East India given growing demand
- Replicate our successful hub and spokes model in East India
- Established a hub in Kolkata and plan is to set up additional diagnostic centres around it
- Hence, Kolkata to be our focus area for medium to long term growth

Preventive and Wellness Testing to Boost Demand for Diagnostics



Key Drivers

- Increasing chronic and lifestyle diseases
- Corporate tie-ups
- Increasing disposable income
- Increasing service offerings

Our Strategy

- Increase diagnostic services by offering additional preventive and wellness services through adoption of new cutting-edge diagnostic testing technology
- Providing home collection services and point-of-contact testing to complement walk-in
- Expand specialty tests, disease specific profiles and provide customized packages
- Grow our corporate customer base by catering to their needs
- Expansion of chronic disease management and wellness programs




**VIJAYA
DIAGNOSTIC
CENTRE**


Financial & Operational Highlights




Diagnostic Centre (Nos)



Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)


Impact of COVID-19



Revenue per Test (INR)




Revenue per Footfall (INR)




Consistent Financial Performance

(INR Mn)


Revenue




EBIDTA




PAT



EBIDTA Margin (%)




PAT Margin (%)




Sustainable Cash Generation & Increasing Return Ratios

Cash & Cash Equivalents


(INR Mn)




CFO / EBIDTA (%)



RoCE Pre-Cash (%)



RoE (%)





**VIJAYA
DIAGNOSTIC
CENTRE**

Annexure

Consolidated Profit & Loss Account



(INR Mn)

Particulars	FY22	FY21	FY20	FY19
Revenue from operations	4,624	3,767	3,388	2,926
Cost of materials consumed	715	571	439	405
Employee benefits expense	707	574	624	539
Other expenses	1,165	962	999	901
EBITDA	2,037	1,660	1,326	1,081
EBITDA %	44.1%	44.1%	39.1%	37.0%
Other income	128	118	154	104
Depreciation and amortization expense	527	505	492	396
EBIT	1,638	1,274	988	789
Finance costs	165	152	154	135
Profit before Tax	1,474	1,121	834	653
Tax expenses	367	270	209	190
Profit after Tax before Minority Interest	1,107	851	625	463
Minority Interest	10	6	0	4
Profit after Tax	1,097	845	625	459
PAT %	23.7%	22.4%	18.5%	15.7%
EPS – Basic (INR)	10.76	8.28	6.13	4.50

Consolidated Balance Sheet

(INR Mn)

Assets	Mar-22	Mar-21	Mar-20	Mar-19
NON-CURRENT ASSETS	4,436	3,022	2,959	2,689
Property, plant and equipment	1,966	1,358	1,398	1,437
Capital work-in-progress	341	82	93	27
Goodwill	53	53	53	69
Other intangible assets	14	6	10	7
Right of use asset	1,672	1,260	1,254	1,079
Intangible assets under development	1	12	4	-
Financial assets				
- Investments	0	0	0	0
- Other financial assets	75	122	55	43
Deferred tax assets	89	61	16	12
Income tax assets	2	6	9	8
Other assets	223	61	67	7
CURRENT ASSETS	2,699	2,388	1,865	1,374
Inventories	43	26	28	22
Financial assets				
- Investments	542	276	547	688
- Trade receivables	98	64	80	91
- Cash and cash equivalents	110	67	556	96
- Bank balances other than Cash and cash equivalents	1,813	1,876	626	430
- Loans	0	0	1	4
- Other financial assets	51	52	5	26
Other current assets	41	27	22	17
TOTAL ASSETS	7,135	5,409	4,824	4,063

EQUITY AND LIABILITIES	Mar-22	Mar-21	Mar-20	Mar-19
EQUITY	4,695	3,592	2,741	2,069
Equity share capital	102	45	45	45
Instruments entirely equity in nature	-	-	-	24
Other equity	4,593	3,547	2,696	2,000
NON-CURRENT LIABILITIES	1,778	1,377	1,494	1,422
Financial liabilities				
- Borrowings	0	33	221	315
- Lease liabilities	1,703	1,265	1,196	1,034
- Other financial liabilities	0	2	9	19
Provisions	74	77	67	53
Other liabilities	1	1	1	1
CURRENT LIABILITIES	661	440	589	572
Financial liabilities				
- Borrowings	6	12	13	20
- Lease liabilities	126	101	88	73
- Trade payables	216	222	217	218
- Other financial liabilities	248	61	224	204
Income tax liabilities	9	16	15	15
Provisions	21	7	11	11
Other liabilities	35	20	21	31
TOTAL EQUITY AND LIABILITIES	7,135	5,409	4,824	4,063

Consolidated Cash Flow Statement

(INR Mn)

Particulars	Mar-22	Mar-21	Mar-20	Mar-19
Cash Flow from Operating Activities				
Profit before Tax	1,474	1,121	834	653
Adjustment for Non-Operating Items	572	534	492	431
Operating Profit before Working Capital Changes	2,046	1,655	1,326	1,084
Changes in Working Capital	-67	-46	-32	8
Cash Generated from Operations	1,975	1,609	1,294	1,092
Less: Direct Taxes paid	-399	-312	-233	-187
Net Cash from Operating Activities	1,580	1,297	1,061	905
Purchase and construction of property, plant and building (net)	-1,223	-312	-375	-591
Investments (net)	-127	-1,033	11	-314
Others	120	47	57	6
Cash Flow from Investing Activities	-1,226	-1,298	-306	-898
Cash Flow from Financing Activities	-306	-488	-295	-72
Net increase/ (decrease) in Cash & Cash equivalent	44	-489	460	-65
Cash & Cash Equivalents at the beginning of the period	67	556	96	161
Cash & Cash equivalents at the end of the period	110	67	556	96

Cash and Cash Equivalents

Particulars	Mar-22	Mar-21	Mar-20	Mar-19
Investments*	543	335	547	688
Cash and cash equivalents	110	67	556	96
Bank balances other than Cash and cash equivalents	1,813	1,876	626	430
Total	2,467	2,277	1,729	1,215



**VIJAYA
DIAGNOSTIC
CENTRE**



THANK YOU

Company

Vijaya Diagnostic Centre Limited (VDCL)



Mr. Siva Rama Raju – Head of Strategy
+91 90597 00749 / +91 99485 95555

sivaramaraju.v@vijayadiagnostic.in
ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Investor Relations Advisors

Citigate Dewe Rogerson (CDR India)

**Mr. Anoop Poojari /
Mr. Devrishi Singh**

**| Citigate Dewe Rogerson Tel: +91 98330 90434 /
+91 98205 30918**

anoop@cdr-india.com
devrishi@cdr-india.com